Abstract
RNAi is a powerful cellular mechanism that involves targeted destruction of mRNAs. Although the phenomenon was first discovered in plants and lower eukaryotic organisms, it was later discovered as an important genetic regulatory mechanism in mammalian cells. RNAi is triggered by double stranded RNAs that are cleaved into short 21-23 base pair duplexes by an RNAse III type enzyme called Dicer. The short RNAs, termed small interfering RNAs (siRNAs), act as triggers for targeted RNA degradation. One of the two strands is selectively incorporated into a complex of proteins called the RNA induced silencing complex, or RISC. The incoroporated small RNA guides the complex to the complementary target sequence, and this event is followed by endonucleolytic cleavage of the target and recycling of RISC. In mammalian cells, siRNAs do not activate interferon pathway genes, thereby making these powerful tools for sequence specific knockdown of RNAs. In this article we review the methods for programming mammalian cells with siRNAs, and overview a number of applications ranging from targeting oncogenes to inhibiting viral replication. The article also summarizes some important biological conclusions that can be drawn from selective downregulation of certain mRNA targets and addresses potential uses of RNAi as a new thereapeutic modality.
Keywords: rnai, rnase III type enzyme, small interfering rnas, rna induced silencing complex
Current Pharmaceutical Biotechnology
Title: Recent Applications of RNAi in Mammalian Systems
Volume: 5 Issue: 4
Author(s): Lisa Scherer and John J. Rossi
Affiliation:
Keywords: rnai, rnase III type enzyme, small interfering rnas, rna induced silencing complex
Abstract: RNAi is a powerful cellular mechanism that involves targeted destruction of mRNAs. Although the phenomenon was first discovered in plants and lower eukaryotic organisms, it was later discovered as an important genetic regulatory mechanism in mammalian cells. RNAi is triggered by double stranded RNAs that are cleaved into short 21-23 base pair duplexes by an RNAse III type enzyme called Dicer. The short RNAs, termed small interfering RNAs (siRNAs), act as triggers for targeted RNA degradation. One of the two strands is selectively incorporated into a complex of proteins called the RNA induced silencing complex, or RISC. The incoroporated small RNA guides the complex to the complementary target sequence, and this event is followed by endonucleolytic cleavage of the target and recycling of RISC. In mammalian cells, siRNAs do not activate interferon pathway genes, thereby making these powerful tools for sequence specific knockdown of RNAs. In this article we review the methods for programming mammalian cells with siRNAs, and overview a number of applications ranging from targeting oncogenes to inhibiting viral replication. The article also summarizes some important biological conclusions that can be drawn from selective downregulation of certain mRNA targets and addresses potential uses of RNAi as a new thereapeutic modality.
Export Options
About this article
Cite this article as:
Scherer Lisa and Rossi J. John, Recent Applications of RNAi in Mammalian Systems, Current Pharmaceutical Biotechnology 2004; 5 (4) . https://dx.doi.org/10.2174/1389201043376724
DOI https://dx.doi.org/10.2174/1389201043376724 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics.
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
Machine Learning and Artificial Intelligence for Medical Data Analysis and Human Information Analysis in Healthcare
The intersection of machine learning (ML) and artificial intelligence (AI) with the pharmaceutical industry is revolutionizing traditional paradigms in drug discovery and development. These technologies have introduced innovative approaches to analyzing complex datasets and predicting chemical properties, leading to more efficient identification and optimization of drug candidates. By employing sophisticated ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Possible Pathways of Hepatotoxicity Caused by Chemical Agents
Current Drug Metabolism Nanocarrier Based Advances in Drug Delivery to Tumor: An Overview
Current Drug Targets Skeletal Muscle in Cancer Cachexia: The Ideal Target of Drug Therapy
Current Cancer Drug Targets Attacking c-Myc: Targeted and Combined Therapies for Cancer
Current Pharmaceutical Design Clinical Development of mTOR Inhibitors: A Focus on Lymphoma
Reviews on Recent Clinical Trials Design of New Oxazaphosphorine Anticancer Drugs
Current Pharmaceutical Design The Current and Future Therapies for Human Osteosarcoma
Current Cancer Therapy Reviews Designing Prodrugs Based on Special Residues of Human Serum Albumin
Current Topics in Medicinal Chemistry Identification and Characterization of the Binding Sites of P-Glycoprotein for Multidrug Resistance-Related Drugs and Modulators
Current Medicinal Chemistry - Anti-Cancer Agents Trabectedin as a New Chemotherapy Option in the Treatment of Relapsed Platinum Sensitive Ovarian Cancer
Current Pharmaceutical Design Cell to Cell Spreading of Misfolded Proteins as a Therapeutic Target in Motor Neuron Disease
Current Medicinal Chemistry Src Inhibitors as Potential Therapeutic Agents for Human Cancers
Mini-Reviews in Medicinal Chemistry The Emerging Role of Poly(ADP-Ribose) Polymerase Inhibitors in Cancer Treatment
Current Drug Targets Is Senescence Reversible?
Current Drug Targets Cellular Targets for Anticancer Strategies
Current Drug Targets Facile Eco-compactable Design for the Synthesis and Characterization of Silver Nanoparticles
Nanoscience & Nanotechnology-Asia Nano Approaches to Enhance Pharmacokinetic and Pharmacodynamic Activity of Plant Origin Drugs
Current Nanoscience Interferon-Related Depression: A Primer on Mechanisms, Treatment, and Prevention of a Common Clinical Problem
Current Neuropharmacology Therapeutic Approach of Primary Bone Tumours by Bisphosphonates
Current Pharmaceutical Design CD4+ T Cell Responses in the Immune Control Against Latent Infection by Epstein-Barr Virus
Current Molecular Medicine